Universal BCMA CAR-T + universal CD19 CAR-T

Universal BCMA CAR-T + universal CD19 CAR-T refers to a combination of two chimeric antigen receptor T cell (CAR-T) therapies engineered to target both B-cell maturation antigen (BCMA) and cluster of differentiation 19 (CD19). These therapies are designed as "universal" or allogeneic products, meaning the T cells are derived from healthy donors rather than the patient, allowing for off-the-shelf use. The mechanism involves genetically modifying donor T cells to express synthetic receptors that recognize and bind to either BCMA or CD19 on malignant B cells or plasma cells. Upon binding, these engineered T cells become activated and kill the cancerous target cell through cytolytic mechanisms such as perforin/granzyme release and cytokine secretion[6][7]. This dual-targeting approach aims to address tumor heterogeneity and reduce relapse due to antigen loss. The primary indications under investigation include relapsed/refractory B-cell malignancies such as acute lymphoblastic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma (for anti-CD19), and multiple myeloma (for anti-BCMA)[2][3][8]. Universal/allogeneic approaches are being developed by several biotechnology companies in early-phase clinical trials.

Other names

Universal BCMA CAR-TUniversal CD19 CAR-TUniversal BCMA and CD19 CAR-TAllogeneic BCMA/CD19 CAR-T